p53 codon 72 polymorphism in bladder cancer - No evidence of association with increased risk or invasiveness

被引：0

作者：

Törüner G.A. ^{[1
]}

Uçar A. ^{[1
]}

Tez M. ^{[2
]}

Çetinkaya M. ^{[3
]}

Özen H. ^{[4
]}

Özçelik T. ^{[1
]}

机构：

[1] Department of Molecular Biology and Genetics, Bilkent University, 06533 Bilkent, Ankara

[2] Atatürk Chest Disease Research Hospital, Ankara

[3] Department of Urology, Ankara Numune Hospital, Ankara

[4] Department of Urology, Faculty of Medicine, Hacettepe University, Ankara

来源：

Urological Research | 2001年 / 29卷 / 6期

关键词：

Bladder cancer; Genetic susceptibility; TP53; polymorphism;

D O I：

10.1007/s002400100218

中图分类号：

学科分类号：

摘要：

We studied the effect of the p53 gene Arg72Pro polymorphism on bladder cancer susceptibility in a case control study of 121 bladder cancer patients and 114 age-sex matched controls to determine whether this polymorphism is a biomarker for the risk and how aggressive the disease is. Genomic DNA was obtained from venous blood samples for genotype determination by PCR and restriction digestion. The genotype frequencies in the patient group were Arg/Arg: 0.3553, Arg/Pro: 0.4711, Pro/Pro: 0.1736, and in the control group Arg/Arg: 0.3684, Arg/Pro: 0.4825, Pro/Pro: 0.1491. The distribution of genotypes between the two groups was not statistically different (χ2 = 0.260, df: 2, P = 0.878). The patient group was subdivided into two groups as superficial bladder cancer (n = 88) and invasive bladder cancer (n = 33), according to the presence of muscle invasion. The distribution of genotypes in the superficial group was Arg/Arg: 0.3409, Arg/Pro: 0.5114, Pro/Pro: 0.1477 and in the invasive group Arg/Arg: 0.3940, Arg/Pro: 0.3636, Pro/Pro: 0.2424. No association was observed with the invasiveness of the tumor (χ2 = 2.542, df: 2, P = 0.281). Stratification of the data by tobacco exposure did not result in a significant difference in genotype frequencies. These data do not support an association between the p53 Arg72Pro polymorphism and bladder cancer.

引用

页码：393 / 395

页数：2

共 15 条

[1]

Chen W.C., Tsai F.J., Wu J.Y., Wu H.C., Lu H.F., Li C.W., Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor, Urol Res, 28, (2000)

[2]

Cordon-Cardo C., Cote R.J., Sauter G., Genetic and molecular markers of urothelial premalignancy and malignancy, Scand J Urol Nephrol Suppl, 205, (2000)

[3]

Fan R., Wu M.T., Miller D., Wain J.C., Kelsey K.T., Wiencke J.K., Christiani D.C., The p53 codon 72 polymorphism and lung cancer risk, Cancer Epidemiol Biomarkers Prey, 9, (2000)

[4]

Griffiths T.R.L., Mellon J.K., Human papillomavirus and urological tumours: II. Role in bladder, prostate, renal and testicular cancer, BJU Int, 85, (2000)

[5]

Guimares D.P., Lu S.H., Snijders P., Wilmotte R., Herrero R., Lenoir G., Montesano R., Meijer C.J.L.M., Walboomers J., Hainaut P., Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high risk area of China, Cancer Lett, 162, (2001)

[6]

Gumus B., Aras O., Atesci Y.Z., Muezzinoglu T., Aetiological factors of bladder cancer in the Aegean region of Turkey between the years 1985-1996, Int Urol Nephrol, 31, (1999)

[7]

Johansson S.L., Cohen S.M., Epidemiology and etiology of bladder cancer, Semin Surg Oncol, 13, (1997)

[8]

Kawaguchi H., Ohno S., Araki K., Miyazaki M., Saeki H., Watanabe M., Tanaka S., Sugimachi K., p53 polymorphism in human papillomavirus-associated esophageal cancer, Cancer Res, 60, (2000)

[9]

Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S.I., Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer, Carcinogenesis, 14, (1993)

[10]

Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L.V., Primary structure polymorphism at amino acid residue 72 of human p53, Mol Cell Biol, 7, (1987)

← 1 2 →